Strathprints logo
Strathprints Home | Open Access | Browse | Search | User area | Copyright | Help | Library Home | SUPrimo

Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma

Joyal, John L and Barrett, John A. and Marquis, John C and Chen, Jianqing and Hillier, Shawn M and Maresca, Kevin P and Boyd, Marie and Gage, Kenneth and Nimmagadda, Sridhar and Kronauge, James F and Friebe, Matthias and Dinkelborg, Ludger and Stubbs, James B and Stabin, Michael G and Mairs, Rob and Pomper, Martin G and Babich, John W (2010) Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma. Cancer Research, 70 (10). pp. 4045-4053.

Full text not available in this repository. (Request a copy from the Strathclyde author)


Radiolabeled benzamides are attractive candidates for targeted radiotherapy of metastatic melanoma as they bind melanin and exhibit high tumor uptake and retention. One such benzamide, N-(2-diethylamino-ethyl)-4-(4-fluoro-benzamido)-5-iodo-2-methoxy-benzamide (MIP-1145), was evaluated for its ability to distinguish melanin-expressing from amelanotic human melanoma cells, and to specifically localize to melanin-containing tumor xenografts. The binding of [(131)I]MIP-1145 to melanoma cells in vitro was melanin dependent, increased over time, and insensitive to mild acid treatment, indicating that it was retained within cells. Cold carrier MIP-1145 did not reduce the binding, consistent with the high capacity of melanin binding of benzamides. In human melanoma xenografts, [(131)I]MIP-1145 exhibited diffuse tissue distribution and washout from all tissues except melanin-expressing tumors. Tumor uptake of 8.82% injected dose per gram (ID/g) was seen at 4 hours postinjection and remained at 5.91% ID/g at 24 hours, with tumor/blood ratios of 25.2 and 197, respectively. Single photon emission computed tomography imaging was consistent with tissue distribution results. The administration of [(131)I]MIP-1145 at 25 MBq or 2.5 GBq/m(2) in single or multiple doses significantly reduced SK-MEL-3 tumor growth, with multiple doses resulting in tumor regression and a durable response for over 125 days. To estimate human dosimetry, gamma camera imaging and pharmacokinetic analysis was performed in cynomolgus monkeys. The melanin-specific binding of [(131)I]MIP-1145 combined with prolonged tumor retention, the ability to significantly inhibit tumor growth, and acceptable projected human dosimetry suggest that it may be effective as a radiotherapeutic pharmaceutical for treating patients with metastatic malignant melanoma.

Item type: Article
ID code: 32464
Notes: (c)2010 AACR.
Keywords: benzamides, drug evaluation, iodine radioisotopes, macaca fascicularis, melanins, melanoma, neoplasm metastasis, radiopharmaceuticals, radiotherapy dosage, tomography, xenograft model antitumor Assays, Therapeutics. Pharmacology, Cancer Research, Oncology
Subjects: Medicine > Therapeutics. Pharmacology
Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
Depositing user: Pure Administrator
Date Deposited: 08 Aug 2011 15:00
Last modified: 21 May 2015 13:32

Actions (login required)

View Item View Item